Array BioPharma (NASDAQ:ARRY) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. In Portfolio Grader’s specific subcategory of Earnings Revisions, ARRY also gets an A. The stock price has risen 42.6% over the past month, better than the 2% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of ARRY stock.
Alnylam Pharmaceuticals (NASDAQ:ALNY) is seeing ratings go up from a B last week to an A this week. Alnylam Pharmaceuticals engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Wall Street has pushed the stock higher by 75.8% over the past month. For more information, get Portfolio Grader’s complete analysis of ALNY stock.
This week, DUSA Pharmaceuticals (NASDAQ:DUSA) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). DUSA Pharmaceuticals is a vertically integrated dermatology company that is developing and marketing pharmaceuticals for the treatment of skin conditions such as actinic keratoses and acne. Wall Street seems to agree with the upgrade and has propelled the stock up 13.4% over the past month. For more information, get Portfolio Grader’s complete analysis of DUSA stock.
This is a strong week for Gentium (NASDAQ:GENT). The company’s rating climbs to B from the previous week’s C. Gentium is a biopharmaceutical company focused on the discovery, research, devel
opment, and manufacture of drugs for the treatment and prevention of a variety of vascular diseases and conditions related to cancer and cancer treatments. Investors seem to agree with the upgraded status of the stock, and have pushed the stock up 5.7% over the past month. For more information, get Portfolio Grader’s complete analysis of GENT stock.
This week, Discovery Laboratories‘s (NASDAQ:DSCO) ratings are up from a C last week to a B. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. Wall Street seems to agree with the upgrade and has propelled the stock up 20.8% over the past month. For more information, get Portfolio Grader’s complete analysis of DSCO stock.
For the latest updates on the stock market, PRESS CTR + D or visit Stock Market Today For the latest updates PRESS CTR + D or visit Stock Market news Today
Related Post:
best stock today
- Why CEDC stock prices down
- Newmont Mining NEM shares analysis next week
- General Motors stock analysis next week
- Amazon stock analysis next week
- Yankee banks bonds are lining up price next week
- Best Health Care Provider stocks strong to buy This week
- Hewlett-Packard HPQ stock november 20 2012
- United parcel service stock Analysis 2013
- stocks to watch next week november 12-16 2012
- UBS raised Tesco stock rating buy oct 17 2012
- JMP Securities raised JPMorgan Chase stock price target oct 15 2012
- Coach share price forecast 2013
- most active stocks pre-market session 9/25/2012
- Caterpillar earnings projection 2015
- Oracle stock prices target
- Why Sharp stock prices jump september 21 2012
- Stocks with historical low P/S ratios
- Citigroup stock prices september 18 2012
- Longbow Research downgraded AMD stock rating
- Newmont stock prices forecast
- AIG may consider dividend summer 2013
- PVH Corp Stock prices august 29 2012
- Yelp stock prices Surged august 29 2012
- U.S. Stocks Movers 8/27/2012
- Hot Stocks to watch 27 - 31 august 2012
No comments:
Post a Comment